Most Read Articles
Jairia Dela Cruz, 05 Oct 2020
Drinking more than two cups of coffee per day may just be the intervention that prevents hundreds of thousands of liver disease‐related deaths globally, a study reports.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.

08 Oct 2020
Diabetes, hypertension, and older age are associated with lower hospital readmission in patients with gastroparesis, while higher length of stay (LOS), drug abuse, and marijuana use increase the 30-day readmission rate, a study has shown.

Budesonide oral suspension improves endoscopic outcomes in eosinophilic oesophagitis

Audrey Abella
08 Jun 2020

Budesonide oral suspension (BOS), a liquid formulation of a topical corticosteroid, improved endoscopic outcomes in patients with eosinophilic oesophagitis (EoE), a phase III trial has shown.

Endoscopic abnormalities are usually present in patients with EoE. [Gastroenterol Clin North Am 2014;43:297-316] Left untreated, EoE may progress into a fibrostenotic phenotype, leading to stricture formation and food impaction. [United European Gastroenterol 2017;5:335-358]

“This study represents the largest trial of EoE, and the first phase III trial of EoE conducted in the US to date … [Our findings reveal that] BOS treatment led to significant improvements from baseline to week 12 vs placebo in [terms of] EREFS* and histologic and symptom responses,” said the researchers.

A total of 318 patients (mean age 34 years, 60 percent male) with EoE and dysphagia were randomized 2:1 to receive BOS 2 mg BID or placebo for 12 weeks. Baseline DSQ** scores and total EREFS between BOS and placebo arms were similar (13.9 vs 13.1 [DSQ] and 3.6 vs 3.3 [EREFS]). [DDW 2020, abstract 227]

There were significantly more BOS than placebo recipients who had histologic (53 percent vs 1 percent; p<0.001) and symptom responses (53 percent vs 39 percent; p=0.02).

Compared with placebo recipients, BOS-treated patients had significantly greater improvements in DSQ score (least-squares mean [LSM], −13.0 vs −9.1; p=0.02), EREFS (LSM, −4.0 vs −2.2 [total], −2.2 vs −1.1 [proximal oesophagus], and −1.8 vs −1.1 [distal oesophagus]; p<0.01 for all), peak eosinophil count (LSM, −55.2 vs −7.6; p<0.001), and EoEHSS*** grade (LSM, −0.2 vs −0.03; p<0.001) and stage scores (LSM, −0.2 vs −0.0; p<0.001).

BOS recipients also had greater improvements in individual EREFS features (p<0.01 for exudates, oedema, furrows; p=0.05 for rings) vs placebo recipients over 12 weeks of therapy.

The significant improvements across EREFS parameters underscore its role as an independent tool to assess EoE disease activity in response to therapy, noted the researchers.

In terms of correlations between changes in total EREFS and other histopathologic parameters in BOS recipients, weak to moderate associations were seen between changes in total EREFS and in peak eosinophil count and EoEHSS grade and stage scores (p<0.01 for all). “[These findings signify the importance of using] endoscopic biopsy in the diagnosis and management of EoE,” said the researchers.

Specifically, in terms of individual EoEHSS features, the strongest correlations in BOS recipients were seen between changes in total EREFS and in EoEHSS scores for basal zone hyperplasia (Pearson correlation coefficient [r], 0.46 [grade] and 0.40 [stage]) and eosinophilic inflammation (r, 0.45 and 0.42, respectively; p<0.01 for all).

Despite the high incidence of any treatment-emergent adverse event (TEAE) in both arms (61 percent), most were mild to moderate in severity. Moreover, there were no life-threatening TEAEs or deaths reported. Treatment discontinuation rate with BOS was low (1.4 percent), suggesting that BOS was generally well tolerated.

“[Overall,] this trial met its coprimary and key secondary efficacy endpoints,” said the researchers. The findings also support an ongoing extension study further exploring the effect of ingesting topical corticosteroids for optimized oesophageal delivery in EoE.

 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 05 Oct 2020
Drinking more than two cups of coffee per day may just be the intervention that prevents hundreds of thousands of liver disease‐related deaths globally, a study reports.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.

08 Oct 2020
Diabetes, hypertension, and older age are associated with lower hospital readmission in patients with gastroparesis, while higher length of stay (LOS), drug abuse, and marijuana use increase the 30-day readmission rate, a study has shown.